162 related articles for article (PubMed ID: 12173317)
1. The clinical use of bone resorption markers in patients with malignant bone disease.
Coleman RE
Cancer; 2002 May; 94(10):2521-33. PubMed ID: 12173317
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
[TBL] [Abstract][Full Text] [Related]
3. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer.
Koizumi M; Takahashi S; Ogata E
Breast Cancer; 2003; 10(1):21-7. PubMed ID: 12525759
[TBL] [Abstract][Full Text] [Related]
4. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
Engler H; Koeberle D; Thuerlimann B; Senn HJ; Riesen WF
Clin Chem Lab Med; 1998 Nov; 36(11):879-85. PubMed ID: 9877095
[TBL] [Abstract][Full Text] [Related]
6. Markers of bone turnover in prostate cancer.
Garnero P
Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A
J Clin Oncol; 2002 Feb; 20(3):850-6. PubMed ID: 11821470
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone turnover in bone metastases.
Fontana A; Delmas PD
Cancer; 2000 Jun; 88(12 Suppl):2952-60. PubMed ID: 10898339
[TBL] [Abstract][Full Text] [Related]
10. [Biomarkers of bone remodelling].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1093-100. PubMed ID: 24158641
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases.
Withold W; Friedrich W; Reinauer H
Ann Clin Biochem; 1996 Sep; 33 ( Pt 5)():421-7. PubMed ID: 8888974
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S138-47. PubMed ID: 14600604
[TBL] [Abstract][Full Text] [Related]
13. Biochemical parameters of bone metabolism in bone metastases of solid tumors (review).
Meijer WG; van der Veer E; Willemse PH
Oncol Rep; 1998; 5(1):5-21. PubMed ID: 9458286
[TBL] [Abstract][Full Text] [Related]
14. Use of markers of bone turnover for monitoring bone metastases and the response to therapy.
Lipton A; Costa L; Ali S; Demers L
Semin Oncol; 2001 Aug; 28(4 Suppl 11):54-9. PubMed ID: 11544577
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of pamidronate in patients with metastatic bone disease.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcemia and bone resorption in malignancy.
Walls J; Bundred N; Howell A
Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
[TBL] [Abstract][Full Text] [Related]
19. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer.
Paterson CR; Robins SP; Horobin JM; Preece PE; Cuschieri A
Br J Cancer; 1991 Nov; 64(5):884-6. PubMed ID: 1931610
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
